The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss for the period | -3,150,228 | -3,073,118 | -954,059 | -197,929 |
| Amortization of right-of-use assets | 35,041 | 34,294 | 15,439 | 29,663 |
| Interest expense | - | - | - | -4,447 |
| Stock-based compensation expense | 9,792 | - | - | - |
| Prepaid expenses | -2,179,230 | -2,332,744 | 8,580,932 | 5,110 |
| Lease liabilities | -35,698 | -40,860 | -15,302 | -29,048 |
| Accounts payable | 5,978 | -112,063 | 114,220 | -4,731 |
| Interest payable | - | - | - | 4,447 |
| Accrued expenses | 1,325 | 1,599 | 5,294 | -4,553 |
| Other current assets | - | - | - | 228,321 |
| Net cash used in operating activities | -954,560 | -857,404 | -9,187,019 | -440,029 |
| Issuance of common stock | - | - | - | 0 |
| Issuance of preferred stock | - | - | - | 0 |
| Proceeds from issuance of common stock, net of underwriting costs - ipo | - | 0 | 15,655,192 | - |
| Loan from shareholders | - | - | - | 400,000 |
| Payment of offering costs | - | 0 | 346,497 | - |
| Net cash provided by financing activities | - | 0 | 14,908,695 | 400,000 |
| Net increase (decrease) in cash | -954,560 | -857,403 | 5,681,646 | - |
| Cash at beginning of period | 4,973,134 | 5,830,537 | 148,891 | - |
| Net increase (decrease) in cash | - | - | - | -40,029 |
| Cash at end of period | 4,018,574 | 4,973,134 | 5,830,537 | - |
Curanex Pharmaceuticals Inc (CURX)
Curanex Pharmaceuticals Inc (CURX)